Compared with the groups treated with PBS, IR780, Tanespimycin, TISN, and IR780+L group, TISN+L group demonstrated a significantly enhanced release of high mobility group protein B1 (HMGB1) and ATP from CT26 tumor cells. The gene discussed is HMGB1; the disease is neoplasm.